CRISPR Therapeutics AG (CRSP)
46.20
-0.09
(-0.19%)
USD |
NASDAQ |
Nov 22, 09:35
CRISPR Therapeutics Total Assets (Quarterly): 2.256B for Sept. 30, 2024
Total Assets (Quarterly) Chart
Historical Total Assets (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 2.256B |
| June 30, 2024 | 2.340B |
| March 31, 2024 | 2.439B |
| December 31, 2023 | 2.230B |
| September 30, 2023 | 2.087B |
| June 30, 2023 | 2.197B |
| March 31, 2023 | 2.244B |
| December 31, 2022 | 2.243B |
| September 30, 2022 | 2.353B |
| June 30, 2022 | 2.463B |
| March 31, 2022 | 2.606B |
| December 31, 2021 | 2.752B |
| September 30, 2021 | 2.822B |
| June 30, 2021 | 2.900B |
| March 31, 2021 | 1.958B |
| December 31, 2020 | 1.828B |
| September 30, 2020 | 1.485B |
| June 30, 2020 | 1.047B |
| Date | Value |
|---|---|
| March 31, 2020 | 1.007B |
| December 31, 2019 | 1.067B |
| September 30, 2019 | 720.59M |
| June 30, 2019 | 494.24M |
| March 31, 2019 | 497.87M |
| December 31, 2018 | 489.02M |
| September 30, 2018 | 518.90M |
| June 30, 2018 | 353.13M |
| March 31, 2018 | 374.45M |
| December 31, 2017 | 271.35M |
| September 30, 2017 | 282.32M |
| June 30, 2017 | 304.98M |
| March 31, 2017 | 322.35M |
| December 31, 2016 | 344.96M |
| September 30, 2016 | 278.65M |
| June 30, 2016 | 293.06M |
| December 31, 2015 | 159.42M |
Total Assets Definition
Assets are a main portion of the balance sheet of a company that measure things that provide economic value. A few examples of assets of a company include cash, inventories, and accounts receivable. From an accounting perspective, the balance sheet equation is Assets = Liabilities + Shareholder's Equity.
Total Assets (Quarterly) Range, Past 5 Years
1.007B
Minimum
Mar 2020
2.900B
Maximum
Jun 2021
2.116B
Average
2.244B
Median
Total Assets (Quarterly) Benchmarks
| Vertex Pharmaceuticals Inc | 22.24B |
| AC Immune SA | 290.33M |
| Addex Therapeutics Ltd | 15.24M |
| NLS Pharmaceutics Ltd | 1.194M |
| Molecular Partners AG | 183.31M |
Total Assets (Quarterly) Related Metrics
| Total Liabilities (Quarterly) | 316.47M |
| Shareholders Equity (Quarterly) | 1.940B |